- Home
- NVCR vs NVAX Comparison
NVCR vs NVAX Comparison
Compare NVCR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- NVAX
- Stock Information
- Founded
- NVCR 2000
- NVAX 1987
- Country
- NVCR Switzerland
- NVAX United States
- Employees
- NVCR N/A
- NVAX N/A
- Industry
- NVCR Medical/Dental Instruments
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVCR Health Care
- NVAX Health Care
- Exchange
- NVCR Nasdaq
- NVAX Nasdaq
- Market Cap
- NVCR 1.9B
- NVAX 1.3B
- IPO Year
- NVCR 2015
- NVAX 1995
- Fundamental
- Price
- NVCR $18.02
- NVAX $6.38
- Analyst Decision
- NVCR Buy
- NVAX Buy
- Analyst Count
- NVCR 6
- NVAX 5
- Target Price
- NVCR $32.83
- NVAX $16.60
- AVG Volume (30 Days)
- NVCR 1.8M
- NVAX 5.5M
- Earning Date
- NVCR 07-24-2025
- NVAX 08-07-2025
- Dividend Yield
- NVCR N/A
- NVAX N/A
- EPS Growth
- NVCR N/A
- NVAX N/A
- EPS
- NVCR N/A
- NVAX 2.97
- Revenue
- NVCR $621,711,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- NVCR $5.56
- NVAX $56.85
- Revenue Next Year
- NVCR $9.19
- NVAX N/A
- P/E Ratio
- NVCR N/A
- NVAX $2.12
- Revenue Growth
- NVCR 18.27
- NVAX 25.92
- 52 Week Low
- NVCR $14.17
- NVAX $5.01
- 52 Week High
- NVCR $34.13
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- NVCR 47.07
- NVAX 44.45
- Support Level
- NVCR $16.19
- NVAX $6.26
- Resistance Level
- NVCR $18.02
- NVAX $6.66
- Average True Range (ATR)
- NVCR 0.88
- NVAX 0.33
- MACD
- NVCR -0.04
- NVAX -0.08
- Stochastic Oscillator
- NVCR 29.74
- NVAX 22.16
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.